Taysha Gene Therapies Q4 2024 Earnings Report $1.60 +0.01 (+0.63%) As of 04:00 PM Eastern Earnings HistoryForecast Taysha Gene Therapies EPS ResultsActual EPS-$0.07Consensus EPS -$0.08Beat/MissBeat by +$0.01One Year Ago EPSN/ATaysha Gene Therapies Revenue ResultsActual Revenue$2.02 millionExpected Revenue$2.05 millionBeat/MissMissed by -$31.00 thousandYoY Revenue GrowthN/ATaysha Gene Therapies Announcement DetailsQuarterQ4 2024Date2/26/2025TimeBefore Market OpensConference Call ResourcesConference CallConference Call TranscriptTSHA Earnings History Taysha Gene Therapies Earnings HeadlinesTruist Financial Keeps Their Buy Rating on Taysha Gene Therapies (TSHA)February 28 at 2:55 AM | markets.businessinsider.comTaysha Gene Therapies, Inc. (NASDAQ:TSHA) Q4 2024 Earnings Call TranscriptFebruary 28 at 2:55 AM | msn.comLong-Forgotten Trump Prophecy Finally Coming True?This shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the biggest "dollar reset" since 1971.February 28, 2025 | Colonial Metals (Ad)Q4 2024 Taysha Gene Therapies Inc Earnings CallFebruary 27 at 3:41 AM | finance.yahoo.comTaysha Gene Therapies Reports 2024 Financial ResultsFebruary 27 at 12:02 AM | tipranks.comTaysha Gene Therapies reports FY24 EPS (36c) vs (96c) last yearFebruary 26 at 10:40 PM | markets.businessinsider.comSee More Taysha Gene Therapies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Taysha Gene Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Taysha Gene Therapies and other key companies, straight to your email. Email Address About Taysha Gene TherapiesTaysha Gene Therapies (NASDAQ:TSHA), a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.View Taysha Gene Therapies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Analysts Lift Archer Aviation Stock Despite Earnings Miss DigitalOcean Rides Cloud Wave and AI Hype to Strong EarningsPrice Targets on NVIDIA Rise in Front of EarningsThe Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance? Upcoming Earnings CrowdStrike (3/4/2025)Arista Networks (3/4/2025)AutoZone (3/4/2025)Target (3/4/2025)Marvell Technology (3/5/2025)Broadcom (3/6/2025)Costco Wholesale (3/6/2025)Oracle (3/10/2025)Adobe (3/12/2025)PDD (3/19/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
